Algernon Pharmaceuticals is a Canadian clinical stage drug development and repurposing company investigating multiple drugs for unmet global medical needs. Algernon Pharmaceuticals has active research programs for IPF with chronic cough, and chronic kidney disease, and is the parent company of a newly created private equity subsidiary called Algernon NeuroScience, that is advancing a psychedelic program investigating a proprietary form of psychedelic DMT for stroke and traumatic brain injury (TBI).
Corporate Fact SheetView Corporate Fact Sheet
Research and Development in the Physical, Engineering, and Life Sciences (541710)
Commercial Physical and Biological Research (8731)
Christopher J. Moreau
Chief Executive Officer
Algernon Pharmaceuticals Inc.
601 West Broadway
Vancouver, BC V5Z 4C2